1. Introduction {#sec1}
===============

Activated charcoal is the gastrointestinal (GI) decontaminating agent that had been regarded as an essential first-line therapy for acute-poisoning patients. However, few studies have shown clinical improvement of poisoned patients who had been treated using activated charcoal. Indications of activated charcoal are decreasing. The indications and use of activated charcoal as a decontamination procedure actually have been declining over the years \[[@B1]--[@B3]\]. American poison centers reported a sharp drop between 1995 and 2016, from 7.7% of all exposures to 1.9%, respectively \[[@B4]\]. The most recent guidelines emphasize that activated charcoal should not be used routinely \[[@B5]\]. However, there are as yet no specific and detailed guidelines on the use of activated charcoal. Indeed, there are significant variations in the use of activated charcoal among clinicians \[[@B6], [@B7]\].

In Korea, premixed activated charcoal with sorbitol had been the only available form of activated charcoal \[[@B8]\]. Due to importation issue, its use was discontinued from 2015. As a result, activated charcoal with sorbitol has been unavailable at our hospital from September of that year. In the present study, we evaluated the clinical outcome differences between the charcoal-available and charcoal-unavailable periods.

2. Materials and Methods {#sec2}
========================

2.1. Study Design and Setting {#sec2.1}
-----------------------------

This study was conducted in an urban academic teaching hospital with an annual emergency department (ED) census of 58000. A retrospective chart review was conducted for the period from January 2013 to January 2017. Patients whose ICD-10-based ED diagnosis was poison-related were selected from electronic medical records. Those who had visited the ED with oral drug overdose, were over 18 years old, and had been exposed within the previous 24 hours were included. Those aged under 18 years, pregnant women, and those suffering caustic ingestion or heavy metal poisoning were excluded.

The subjects\' age, sex, clinical parameters such as vital signs, Glasgow Coma Scale (GCS), underlying diseases, laboratory results, and clinical outcomes were collected. Aspiration pneumonia was defined as newly developed lung lesions on chest X-ray or computed tomography and worsening of respiratory symptoms within 48 hours of admission \[[@B9], [@B10]\].

This study was approved by the Institutional Review Board (IRB) of the study hospital (IRB no. 20170626/30-2017-15/073). Informed consent was waived by the IRB.

2.2. Statistical Analysis {#sec2.2}
-------------------------

Mortality, endotracheal intubation and vasopressor use, development of aspiration pneumonia, intensive care unit (ICU) admission, and hospital admission were evaluated as clinical outcomes.

A subgroup analysis was performed for factors that can affect the clinical efficacy of activated charcoal based on previous studies \[[@B11]--[@B13]\]. Moreover, we defined the conditions under which activated charcoal can be beneficial: (1) patient presents within 2 hours of ingestion, (2) GCS 13-15 on arrival, and (3) potentially toxic ingestion (excluding ingestion of less toxic substance such as benzodiazepines and sedatives, as well as cases of ingestion of relatively small amounts) \[[@B5]\]. Two board-certified emergency physicians decide whether there is potential toxic exposure or not.

The Shapiro-Wilk test was used to evaluate the normality of the continuous variables, which were expressed as a mean ± standard deviation or median (interquartile range), as appropriate. Categorical variables were summarized by frequency according to the corresponding percentage and compared using the chi-square test or Fisher\'s exact test as appropriate.

All of the analyses were performed with SPSS 22 (IBM, Armonk, New York, USA). A p value less than 0.05 was considered to indicate statistical significance.

3. Results {#sec3}
==========

3.1. Characteristics of the Patients {#sec3.1}
------------------------------------

In this retrospective cohort study, we identified 634 patients who met the study criteria. Four hundred and thirteen (413) patients were managed during the activated charcoal-available period and 221 during the activated charcoal-unavailable period ([Table 1](#tab1){ref-type="table"}). Activated charcoal was used in the treatment of 141 patients (34.0%) during the activated charcoal-available period. No enrolled patient received multiple-dose charcoal.

There was no interperiod difference in patient age, sex, medical history, or vital signs. There were statistical interperiod differences in some initial laboratory values (sodium, creatine kinase-MB, troponin I, and activated partial thromboplastin time) ([Table 1](#tab1){ref-type="table"}), though they were minimal and not clinically significant. Gastric lavage was more frequently performed in the activated charcoal-available period (26.4%) than in the activated charcoal-unavailable period (10%) (*p* \< 0.001). The ingested toxic substances of both groups are presented in [Table 2](#tab2){ref-type="table"}.

3.2. Charcoal Availability and Clinical Outcome {#sec3.2}
-----------------------------------------------

There were no differences in the incidence of aspiration pneumonia, the rate of intubation, vasopressor use, or mortality between the charcoal-available and charcoal-unavailable periods ([Table 3](#tab3){ref-type="table"}).

The rates of hospital admission (43.3 versus 29.9%,*p* \< 0.001) and ICU admission (5.8 versus 13.6%,*p* \< 0.001) were higher in the charcoal-unavailable period; however, the number of ICU days was lower and the total hospital stay was shorter ([Table 3](#tab3){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}).

3.3. GCS and Clinical Outcomes according to Charcoal Availability {#sec3.3}
-----------------------------------------------------------------

According to the GCS levels, there were no interperiod differences in aspiration pneumonia, intubation, vasopressor use, or mortality. In the charcoal-unavailable period, hospital admission was less common and the rate of ICU admission was higher for patients with preserved mental status (GCS 13-15) ([Table 3](#tab3){ref-type="table"}). During the charcoal-available period, both hospital admission and ICU admission were more common for charcoal-administered patients ([Table 4](#tab4){ref-type="table"}).

3.4. Single- and Multiple-Drug Ingestions and Clinical Outcome according to Activated Charcoal Availability {#sec3.4}
-----------------------------------------------------------------------------------------------------------

Higher hospital admission rates and lower ICU admission rates during the charcoal-unavailable period were observed among the single-drug-poisoned patients. The other clinical outcomes did not differ between the periods for either single- or multiple-drugs-poisoned patients ([Table 5](#tab5){ref-type="table"}).

3.5. Presenting Time and Clinical Outcome according to Activated Charcoal Availability {#sec3.5}
--------------------------------------------------------------------------------------

Higher hospital admission rates and lower ICU admission rates during the charcoal-unavailable period also were observed among the patients with a time delay of more than 1 hour from ingestion to ED visit ([Table 6](#tab6){ref-type="table"}). The other clinical outcomes did not differ between the periods. During the charcoal-available period, intubations were more commonly conducted for patients who had arrived at the ED within 1 hour and received activated charcoal (11.4 versus 9.1%,*p* = 0.015) ([Table 6](#tab6){ref-type="table"}).

3.6. Clinical Outcomes of Patients Who May Benefit from Activated Charcoal {#sec3.6}
--------------------------------------------------------------------------

Twenty-three patients and 17 patients were identified during the charcoal-available and charcoal-unavailable periods, respectively. Activated charcoal was used for 12 patients (52.1%) during the charcoal-available period. There were no differences in clinical outcomes between the periods ([Table 7](#tab7){ref-type="table"}) (Supplemental [Table 2](#supplementary-material-1){ref-type="supplementary-material"}).

3.7. Mortality Cases {#sec3.7}
--------------------

Among the mortality cases, only one patient visited within 2 hours of exposure. His age was 92 and he died due to aspiration pneumonia. Charcoal was not used, because of decreased consciousness, sedative poisoning, and high risk of respiratory complication. He died from respiratory complications 18 days from ED visit ([Table 8](#tab8){ref-type="table"}). Other patients visited the ED 4 hours or more after exposure to toxins ([Table 8](#tab8){ref-type="table"}).

4. Discussion {#sec4}
=============

Activated charcoal has been used for the treatment of poisoned patients for more than 100 years and remains the major GI decontamination therapy for such cases \[[@B1], [@B2], [@B5], [@B14]\].

Many preclinical studies have shown beneficial effects of activated charcoal in various kinds of drug poisonings \[[@B5], [@B15]--[@B19]\]. However, few clinical studies have established any clinical benefits of activated charcoal use \[[@B1], [@B2], [@B5], [@B14]\]. One retrospective study showed activated charcoal within 2 hours of a paracetamol ingestion is associated with a decreased requirement for N-acetylcysteine \[[@B20]\]. A recent prospective study on massive paracetamol overdose found a benefit of activated charcoal use within 4 hours. Within that time, development of hepatotoxicity (peak ALT \> 1000 U/L) was lower in the charcoal-treated patients. However, only serum liver enzyme levels were evaluated as an outcome and mortality, hospital day, presence and severity of hepatic encephalopathy, and liver transplantation were not \[[@B21]\].

Various clinical studies have failed to prove any clinical benefits of activated charcoal \[[@B8], [@B13], [@B22]--[@B24]\]. In a prospective ED study, there was no improvement of the clinical outcomes of single-dose activated charcoal. Activated charcoal use was associated with longer ED stay and higher incidence of vomiting. However, ICU admission, length of ICU and hospital stay, length of intubation time, and development of aspiration pneumonia were found to be unrelated to activated charcoal use \[[@B13]\]. One recent prospective study showed that age was the only factor associated with clinical improvement in case of drug poisoning, activated charcoal administration was determined to be unrelated to clinical outcome \[[@B24]\].

The reasons for the discrepancies between the results of preclinical and clinical studies are not clear. The risk of charcoal-induced aspiration might be one explanation. Chemical pneumonitis due to direct charcoal exposure is a fatal complication and has been, to say the least, a major concern \[[@B5], [@B25]--[@B29]\]. Development of aspiration pneumonitis in overdose patients has been related to poor prognosis \[[@B10], [@B11]\]. Activated charcoal use in instance of nonintubation and decreased mental status has been related to aspiration pneumonia \[[@B10]\]. However, other clinical studies have shown minimal risk of aspiration pneumonitis and pneumonia in the use of activated charcoal \[[@B30]--[@B32]\]. One retrospective study found that the incidence of pulmonary aspiration was only 0.6% in patients who had received multiple doses of activated charcoal \[[@B30]\]. An analysis of a toxicology-unit admission cohort showed a prevalence of aspiration pneumonitis of 11% and established that the predictors did not include activated charcoal use but rather age, emesis, and time delay from ingestion to hospital \[[@B32]\].

It is well known that airway protection is important for prevention of aspiration pneumonitis in poisoned patients \[[@B9]\]. The current guidelines emphasize airway protection prior to activated charcoal use \[[@B1], [@B2], [@B5]\]. In our study, intubations also were conducted more frequently for charcoal-administered patients (18, 51.4%) than for not-administered patients (17, 6.3%) (*p*= 0.024) in the charcoal-available period.

In our study, mortality, need of vasopressor, intubation, and incidence of aspiration pneumonia were not affected by charcoal availability ([Table 3](#tab3){ref-type="table"}). Within the charcoal-available period, aspiration pneumonia developed in 13 (9.2%) of the charcoal-administered patients and 28 (10.3%) of the not-administered patients, of which difference was not significant (*p* = 0.729).

The ICU admission rate was increased in the charcoal-unavailable periods. However, the total hospital admission rate was lower ([Table 3](#tab3){ref-type="table"}). For patients admitted to ICU, the number of ICU days and total hospital days were shorter in the charcoal-unavailable period (5 \[[@B3]--[@B10]\] versus 2 \[[@B1]--[@B5]\],*p* = 0.010 and, 10 \[[@B4]--[@B19]\] versus 4 \[[@B3]--[@B9]\],*p* = 0.021, respectively) ([Figure 1](#fig1){ref-type="fig"}). Because ICU days were shorter in the charcoal-unavailable period, the increase in the ICU admission rate might have been the result of concerns about activated charcoal unavailability.

In our study, most of the deaths occurred when the visit to the ED was delayed ([Table 8](#tab8){ref-type="table"}). Delayed ED presentation can cause worsening of poisoning \[[@B33]\]. Early adequate supportive care seems to be a more cardinal treatment process than activated charcoal use.

The rate of activated charcoal use was high in charcoal-available period (34.1%). Nearly half (42%) of patients received the activated charcoal more than 2 hours after exposure to toxins. A Norwegian study reported 16% activated charcoal use for all admitted acute-poisoning patients in Oslo \[[@B34], [@B35]\]. However, our study also showed a low mortality rate in both the charcoal-available and charcoal-unavailable periods. These findings indirectly show that adequate supportive care is essential to the treatment of oral drug poisoned patients.

There are several limitations to this study. First, it is a retrospective study. Neither randomization or nor blinding was applied, and clinical decisions might have been affected by charcoal-availability. Second, the severity of poisoning was not high; the total mortality was only 1.6% (10 patients). Considering that activated charcoal is more beneficial for severe poisoning, its effect might have been underestimated \[[@B1], [@B2]\]. High mortality was observed among the delayed ED visit patients. Third, we included only adult patients and oral drug poisonings other than from plants, mushrooms, herbicides, and pesticides. Fourth, gastric lavage was used as a GI decontaminating agent in both periods and which can attenuate the clinical effects of charcoal unavailability. Finally, the exact substances or amounts could not be identified in many cases and thus were not fully evaluated in this study.

5. Conclusions {#sec5}
==============

Between the charcoal-available and charcoal-unavailable periods, activated charcoal availability was unrelated to mortality, incidence of aspiration pneumonia, intubation, or use of vasopressor for treatment of oral drug poisoned patients.
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=================

The data used to support the findings of this study are available from the corresponding author upon request.
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###### 

Supplemental Table 1: time delay from drug exposure to presentation. Supplemental Table 2: major toxic agents of patients who may benefit from activated charcoal*∗*. NSAID: Nonsteroidal Anti-Inflammatory Drugs. *∗*: (1) present within 2 hours of acute overdose, (2) GCS 13-15 on arrival, and (3) potential toxic ingestion.

###### 

Click here for additional data file.

![Length of stay of patients admitted to ICU between charcoal-available and charcoal-unavailable periods.^*∗*^   ^*∗*^One extreme outlier case is present in charcoal-unavailable period (41 ICU days and 91 total hospital days).](EMI2018-4642127.001){#fig1}

###### 

Patient characteristics.

                                              Charcoal-available period   Charcoal-unavailable period   *p*-value
  ------------------------------------------- --------------------------- ----------------------------- -----------
  Age, median (IQR)                           41 (28-58)                  43                            0.267
  Male, n (%)                                 148 (35.8%)                 77                            0.803
  Medical History                                                                                        
   Hypertension, n (%)                        72 (17.4%)                  32 (14.5%)                    0.339
   Diabetes mellitus, n (%)                   40 (9.7%)                   19 (8.6%)                     0.653
  Multiple drug ingestion                     242 (58.6%)                 119 (53.8%)                   0.250
  Vital signs                                                                                            
   Mean blood pressure (mmHg), median (IQR)   93 (79-103)                 94 (77-107)                   0.495
   Heart rate (/min), median (IQR)            90 (79-100)                 87 (76-103)                   0.258
   Respiratory rate (/min), median (IQR)      20 (18-20)                  20 (18-20)                    0.168
   Body temperature (°C), median (IQR)        36.2 (36.0-36.6)            36.4 (36.0-36.7)              0.102
  GCS, median (IQR)                           14 (11-15)                  14 (10-15)                    0.971
  Laboratory results                                                                                     
   WBC (x10^3^/*μℓ*), median (IQR)            7.55 (5.76-10.19)           7.44 (5.96-9.82)              0.996
   Hemoglobin (g/d*ℓ*), median (IQR)          13.5 (12.6-14.6)            13.4 (12.2-14.6)              0.374
   Platelet (*∗*1000/*μℓ*), median (IQR)      249 (205.5-299.5)           249 (202-298.5)               0.970
   Sodium (mmol/*ℓ*), median (IQR)            139.1 (137.3-140.9)         138.6 (136.6-140.6)           0.046
   Potassium (mmol/*ℓ*), median (IQR)         3.8 (3.54-4.12)             3.8 (3.50-4.00)               0.429
   Total CO~2~ (mmol/*ℓ*), median (IQR)       22.8 (20.90-26.26)          22.3 (20.15-26.50)            0.082
   BUN (mg/d*ℓ*), median (IQR)                12 (9-16)                   13 (11-16)                    0.167
   Creatinine (mg/d*ℓ*), median, (IQR)        0.74 (0.61-0.89)            0.74 (0.65-0.91)              0.242
   AST (IU/*ℓ*), median, (IQR)                25 (19-37)                  25 (19-28)                    0.880
   ALT (IU/*ℓ*), median, (IQR)                15 (10-25)                  15 (10-29)                    0.772
   CRP (mg/d*ℓ*), median, (IQR)               0.08 (0.03-0.24)            0.07 (0.02-0.26)              0.501
   CK (IU/*ℓ*), median, (IQR)                 97 (69-151)                 96 (68-159)                   0.838
   CK-MB (ng/mL), median (IQR)                0.5 (0.5-1.1)               0.9 (0.6-2.1)                 \< 0.001
   Troponin I (ng/mL), median (IQR)           0.04 (0.04-0.04)            0.02 (0.01-0.02)              \< 0.001
   aPTT (seconds), median (IQR)               25.9 (23.0-28.7)            27.2 (25.0-30.3)              \< 0.001
   PT (INR), median (IQR)                     1.06 (1.01-1.11)            1.06 (1.01-1.12)              0.836
  Gastric lavage, n (%)                       109 (26.4%)                 22 (10%)                      \< 0.001
  Activated charcoal, use n (%)               141 (34.1%)                 0 (0%)                        \< 0.001
  SOFA score*∗*                               6 (4-7)                     5 (3-6)                       0.153

GCS: Glasgow Coma Scale; WBC: white blood cells; BUN: blood urea nitrogen; AST: aspartate transaminase; ALT: alanine aminotransferase; CRP: C-reactive protein; CK: creatine kinase; CK-MB: creatine kinase-MB; aPTT: activated partial thromboplastin time; PT: prothrombin time; SOFA: sequential organ failure assessment.

*∗*Only for ICU patients.

###### 

Toxic substances ingested by patients.

                                   Charcoal-available period   Charcoal-unavailable period
  -------------------------------- --------------------------- -----------------------------
  CNS Affecting Drug, n (%) *∗*    134 (32.4%)                 77 (34.8%)
  Benzodiazepine, n (%)            21 (5.1%)                   8 (3.6%)
  Acetaminophen, n (%)             16 (3.9%)                   8 (3.6%)
  Cardiovascular drug, n (%)       4 (1.0%)                    4 (1.8%)
  Salicylate, n (%)                6 (1.5%)                    1 (0.5%)
  OTC drugs, n (%) †               9 (2.2%)                    7 (3.2%)
  Two or more toxin types, n (%)   132 (32.0%)                 73 (33.0%)
  Others, n (%)                    51 (12.3%)                  26 (11.8%)
  Unknown, n (%)                   40 (9.7%)                   17 (7.7%)

CNS: central nervous system; OTC: over the counter.

*∗*Except benzodiazepine.

^†^Substances not clearly identified.

###### 

Charcoal availability and clinical outcome.

                                   Charcoal-available period   Charcoal-unavailable period   *p*-value
  -------------------------------- --------------------------- ----------------------------- -----------
  Aspiration pneumonia, n (%)      41 (9.9%)                   21 (9.5%)                     0.864
  Endotracheal intubation, n (%)   35 (8.5%)                   16 (7.2%)                     0.586
  Vasopressor, n (%)               22 (5.3%)                   11 (5.0%)                     0.850
  Mortality, n (%)                 8 (1.9%)                    2 (0.9%)                      0.507
  Hospital admission, n (%)        179 (43.3%)                 66 (29.9%)                    \<0.001
  ICU admission, n (%)             24 (5.8%)                   30 (13.6%)                    \<0.001

ICU: intensive care unit.

###### 

GCS and clinical outcomes compared between charcoal-available and charcoal-unavailable periods.

                         Charcoal-available period   Charcoal-unavailable period   *p-*value^†^                          
  ---------------------- --------------------------- ----------------------------- -------------- --------- ------------ ---------
  Aspiration pneumonia                                                                                                    
   GCS 13-15             7 (4.0%)                    7 (7.4%)                      14 (5.2%)      0.258     3 (2.1%)     0.119
   GCS 9-12              7 (13.7%)                   3 (10.7%)                     10 (12.7%)     \>0.990   4 (10.8%)    \>0.999
   GCS 3-8               14 (29.2%)                  3 (15.8%)                     17 (25.4%)     0.356     14 (36.8%)   0.216
  Intubation                                                                                                              
   GCS 13-15             3 (1.7%)                    6 (6.4%)                      9 (3.4%)       0.071     3 (2.1%)     0.552
   GCS 9-12              5 (9.8%)                    4 (14.3%)                     9 (11.4%)      0.713     3 (8.1%)     0.749
   GCS 3-8               9 (18.8%)                   8 (47.1%)                     17 (25.4%)     0.064     10 (26.3%)   0.915
  Vasopressor use                                                                                                         
   GCS 13-15             7 (4.0%)                    3 (3.2%)                      10 (3.7%)      \>0.990   5 (3.4%)     0.868
   GCS 9-12              4 (7.8%)                    1 (3.6%)                      5 (6.3%)       0.651     1 (2.7%)     0.663
   GCS 3-8               6 (12.5%)                   1 (5.3%)                      7 (10.4%)      0.663     5 (13.2%)    0.753
  Mortality                                                                                                               
   GCS 13-15             3 (1.7%)                    1 (1.1%)                      4 (1.5%)       \>0.990   1 (0.7%)     0.660
   GCS 9-12              1 (2.0%)                    0 (0%)                        1 (1.3%)       \>0.990   1 (2.7%)     0.538
   GCS 3-8               3 (6.3%)                    0 (0%)                        3 (4.5%)       0.553     0 (0%)       0.552
  Hospital admission                                                                                                      
   GCS 13-15             50 (28.9%)                  39 (41.5%)                    89 (33.3%)     0.037     28 (19.2%)   0.002
   GCS 9-12              26 (51.0%)                  17 (60.7%)                    43 (54.4%)     0.046     15 (40.5%)   0.163
   GCS 3-8               36 (75.6%)                  11 (57.9%)                    47 (70.1%)     0.168     23 (60.5%)   0.315
  ICU admission                                                                                                           
   GCS 13-15             2 (1.2%)                    6 (6.4%)                      8 (3.0%)       0.024     12 (8.2%)    0.028
   GCS 9-12              3 (5.9%)                    2 (7.1%)                      5 (6.3%)       \>0.990   6 (16.2%)    0.102
   GCS 3-8               7 (14.6%)                   4 (21.1%)                     11 (16.4%)     0.492     12 (31.6%)   0.071
  Number of patients                                                                                                      
   GCS 13-15             173                         94                            267                      146           
   GCS 9-12              51                          28                            79                       37            
   GCS 3-8               48                          19                            67                       38            

GCS: Glasgow Coma Scale; ICU: intensive care unit.

^*∗*^between noncharcoal and charcoal.

^†^Between charcoal-available and charcoal-unavailable periods.

###### 

Multiple-drug ingestion and clinical outcomes compared between charcoal-available and charcoal-unavailable periods.

                         Charcoal-available period   Charcoal -unavailable period   *p-*value^†^                        
  ---------------------- --------------------------- ------------------------------ -------------- ------- ------------ ---------
  Aspiration pneumonia                                                                                                   
   single drug           11 (9.9%)                   8 (13.3%)                      19 (11.1%)     0.497   11 (10.8%)   0.933
   multiple drug         17 (10.6%)                  5 (6.2%)                       22 (9.1%)      0.263   10 (8.4%)    0.829
  Intubation                                                                                                             
   single drug           8 (7.2%)                    9 (15.0%)                      17 (9.9%)      0.104   8 (7.8%)     0.561
   multiple drug         9 (5.6%)                    9 (11.1%)                      18 (7.4%)      0.122   8 (6.7%)     0.805
  Vasopressor use                                                                                                        
   single drug           5 (4.5%)                    1 (1.7%)                       6 (3.5%)       0.666   7 (6.9%)     0.245
   multiple drug         12 (7.5%)                   4 (4.9%)                       16 (6.6%)      0.588   4 (3.4%)     0.204
  Mortality                                                                                                              
   single drug           3 (2.7%)                    0 (0%)                         3 (1.8%)       0.553   1 (1.0%)     \>0.999
   multiple drug         4 (2.5%)                    1 (1.2%)                       5 (2.1%)       0.667   1 (0.8%)     0.668
  Hospital admission                                                                                                     
   single drug           49 (44.1%)                  30 (50.0%)                     79 (46.2%)     0.464   33 (32.4%)   0.024
   multiple drug         63 (39.1%)                  37 (45.7%)                     100 (41.3%)    0.329   33 (24.8%)   0.012
  ICU admission                                                                                                          
   single drug           2 (1.8%)                    7 (11.7%)                      9 (5.3%)       0.010   16 (15.7%)   0.004
   multiple drug         10 (6.2%)                   5 (6.2%)                       15 (6.2%)      0.991   14 (11.8%)   0.067
  Number of patients                                                                                                     
   single drug           111                         60                             171                    102           
   multiple drug         161                         81                             242                    119           

GCS: Glasgow Coma Scale; ICU: intensive care unit.

^*∗*^between noncharcoal and charcoal.

^†^Between charcoal-available and charcoal-unavailable period.

###### 

Time delay from drug ingestion to ED visit and clinical outcome between charcoal-available and charcoal-unavailable periods.

                         Charcoal-available period   Charcoal-unavailable period   *p-*value^†^                        
  ---------------------- --------------------------- ----------------------------- -------------- ------- ------------ ---------
  Aspiration pneumonia                                                                                                  
   within 1hr            5 (7.6%)                    3 (6.8%)                      8 (7.3%)       1       5 (7.8%)     0.818
   over 1hr              23 (11.2%)                  10 (10.3%)                    33 (10.9%)     0.823   16 (10.2%)   \>0.999
  Intubation                                                                                                            
   within 1hr            6 (9.1%)                    5 (11.4%)                     11 (10%)       0.015   3 (4.7%)     0.214
   over 1hr              11 (5.3%)                   13 (13.4%)                    24 (7.9%)      0.697   13 (8.3%)    0.893
  Vasopressor use                                                                                                       
   within 1hr            1 (1.5%)                    0 (0%)                        1 (0.9%)       1       3 (4.7%)     0.141
   over 1hr              16 (7.8%)                   5 (5.2%)                      21 (6.9%)      0.404   8 (5.1%)     0.443
  Mortality                                                                                                             
   within 1hr            0 (0%)                      0 (0%)                        0 (0%)         NA      0 (0%)       N/A
   over 1hr              7 (3.4%)                    1 (1.0%)                      8 (2.6%)       0.231   2 (1.3%)     0.506
  Hospital admission                                                                                                    
   within 1hr            17 (25.8%)                  20 (45.5%)                    37 (33.6%)     0.339   15 (23.4%)   0.156
   over 1hr              95 (46.1%)                  47 (48.5%)                    142 (46.9%)    0.171   51 (32.5%)   0.003
  ICU admission                                                                                                         
   within 1hr            3 (4.5%)                    4 (9.1%)                      7 (6.4%)       0.434   7 (10.9%)    0.285
   over 1hr              9 (4.4%)                    8 (8.2%)                      17 (5.6%)      0.171   23 (14.6%)   0.001
  Number of patients                                                                                                    
   within 1hr            66                          44                            110                    64            
   over 1hr              206                         97                            303                    157           

GCS: Glasgow Coma Scale; ICU: intensive care unit.

^*∗*^between noncharcoal and charcoal.

^†^Between charcoal-available and charcoal-unavailable period.

###### 

Clinical outcomes of patients who may benefit from activated charcoal use*∗*.

                                                               Charcoal-available period   Charcoal-unavailable period   *p*-value
  ------------------------------------------------------------ --------------------------- ----------------------------- -----------
  Aspiration pneumonia, n (%)                                  2 (8.7%)                    1 (5.9%)                      0.615
  Endotracheal intubation, n (%)                               1 (4.3%)                    1 (5.9%)                      \>0.999
  Endotracheal intubation after 4 hours from ED visit, n (%)   1 (4.3%)                    0 (0%)                        \>0.999
  Vasopressor, n (%)                                           0 (0%)                      2 (11.8%)                     0.174
  Vasopressor after 4 hours from ED visit, n (%)               0 (0%)                      1 (5.9%)                      0.436
  Mortality, n (%)                                             0 (0%)                      0 (0%)                        NA
  Hospital admission, n (%)                                    8 (34.8%)                   5 (29.4%)                     0.072
  ICU admission, n (%)                                         1 (4.3%)                    3 (17.6%)                     0.294
  Prolonged ICU admission                                      1 (4.3%)                    1 (5.9%)                      \>0.999

ICU: intensive care unit.

*∗*: (1) present within 2 hours of acute overdose, (2) GCS 13-15 on arrival, and (3) potential toxic ingestion.

###### 

Summary of mortality cases.

  Period                 Sex      Age   Activated charcoal use   Time delay   Survival time   Toxic substances
  ---------------------- -------- ----- ------------------------ ------------ --------------- -------------------------------------------------
  Charcoal-available     male     92    \-                       2 hours      18 days         Sedatives
  Charcoal-available     female   78    \-                       4 hours      2 days          Unidentified
  Charcoal-available     male     29    \-                       17 hours     16 hours        Salicylate
  Charcoal-available     female   66    \-                       8 hours      12 hours        Antidepressants
  Charcoal-available     female   17    \-                       7 hours      7 hours         Bupropion
  Charcoal-available     male     72    \-                       12 hours     1 days          Antipsychotics
  Charcoal-available     female   70    \-                       6 hours      12 hours        Multiple drug including betablocker
  Charcoal-available     male     56    \+                       4 hours      10 days         Multiple unidentified drugs including sedatives
  Charcoal-unavailable   male     77    \-                       6 hours      4 days          Multiple antipsychotics
  Charcoal-unavailable   male     61    \-                       4 hours      3 days          Unknown

[^1]: Academic Editor: Marco L. A. Sivilotti
